Bonus BioGroup (BONS) Stock Overview
A clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BONS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bonus BioGroup Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.33 |
| 52 Week High | ₪0.61 |
| 52 Week Low | ₪0.19 |
| Beta | 0.78 |
| 1 Month Change | -13.47% |
| 3 Month Change | -12.11% |
| 1 Year Change | 62.14% |
| 3 Year Change | 118.30% |
| 5 Year Change | -71.89% |
| Change since IPO | 39.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| BONS | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 1.8% | 0.2% | -2.1% |
| 1Y | 62.1% | -15.1% | 17.2% |
Return vs Industry: BONS exceeded the IL Biotechs industry which returned -15.4% over the past year.
Return vs Market: BONS exceeded the IL Market which returned 20.1% over the past year.
Price Volatility
| BONS volatility | |
|---|---|
| BONS Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IL Market | 9.7% |
| 10% least volatile stocks in IL Market | 3.7% |
Stable Share Price: BONS's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: BONS's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 42 | Shai Meretzki | bonus-bio.com |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome.
Bonus BioGroup Ltd. Fundamentals Summary
| BONS fundamental statistics | |
|---|---|
| Market cap | ₪390.16m |
| Earnings (TTM) | -₪24.49m |
| Revenue (TTM) | n/a |
Is BONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONS income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪24.49m |
| Earnings | -₪24.49m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BONS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 12:47 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonus BioGroup Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.